Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
Narcolepsy01:07

Narcolepsy

Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy, safety, and tolerability of low sodium oxybate for nocturnal cluster headache attacks in chronic cluster headache: protocol for a phase II randomized, double-blind, placebo-controlled, trial (SUNCET).

Pain management·2026
Same author

From accepting to distancing as different coping strategies in persons with young onset Parkinson's disease.

NPJ Parkinson's disease·2026
Same author

Hydrocephalus induced chorea.

BMJ case reports·2025
Same author

Corticotropin-Releasing Hormone (CRH) in Murine Narcolepsy: What Do Genetic and Immune Models Tell Us?

Journal of sleep research·2025
Same author

Deep clustering of polysomnography data to characterize sleep structure in healthy sleep and non-rapid eye movement parasomnias.

Journal of neuroscience methods·2025
Same author

Symptoms of central disorders of hypersomnolence during phases of female hormonal transitions: an explorative self-report study.

Sleep medicine·2025

Related Experiment Video

Updated: Jul 10, 2026

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
06:22

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

CSF hypocretin-1 levels are normal in multiple-system atrophy.

W F Abdo1, B R Bloem, H P H Kremer

  • 1Institute of Neurology, Department of Neurology, Radboud University Nijmegen Medical Centre, 830 LKN, P.O. Box 9101, 6500 Nijmegan, HB, The Netherlands.

Parkinsonism & Related Disorders
|November 3, 2007
PubMed
Summary

Sleep disturbances are common in multiple system atrophy (MSA). This study found no difference in CSF hypocretin-1 levels between MSA patients and controls, suggesting other causes for sleep issues.

More Related Videos

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice
06:40

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice

Published on: March 19, 2018

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Related Experiment Videos

Last Updated: Jul 10, 2026

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid
06:22

A Pilot Study on the Repetitive Transcranial Magnetic Stimulation of Aβ and Tau Levels in Rhesus Monkey Cerebrospinal Fluid

Published on: September 3, 2021

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice
06:40

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice

Published on: March 19, 2018

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Area of Science:

  • Neuroscience
  • Neurology
  • Sleep Medicine

Background:

  • Sleep disturbances affect up to 70% of patients with multiple system atrophy (MSA).
  • Hypothalamic hypocretin (orexin) neurotransmission is implicated in sleep regulation and has been suggested as a potential factor in MSA-related sleep disturbances.
  • Previous research has not systematically investigated cerebrospinal fluid (CSF) hypocretin-1 levels in MSA patients.

Purpose of the Study:

  • To systematically analyze CSF hypocretin-1 concentrations in patients with multiple system atrophy (MSA).
  • To investigate the potential role of hypocretin-1 deficiency in sleep disturbances observed in MSA.

Main Methods:

  • Cerebrospinal fluid (CSF) hypocretin-1 concentrations were measured.
  • Analyzed samples from 6 patients with MSA-Parkinsonian subtype (MSA-P), 6 patients with MSA-Cerebellar subtype (MSA-C), and 11 age-matched healthy controls.

Main Results:

  • No significant differences were observed in CSF hypocretin-1 levels between MSA patients (both MSA-P and MSA-C) and the control group.
  • CSF hypocretin-1 concentrations in MSA patients were comparable to those in age-matched controls.

Conclusions:

  • The findings do not support a deficiency in CSF hypocretin-1 as the primary cause of sleep disturbances in multiple system atrophy.
  • Alternative mechanisms or neurotransmitter systems may be responsible for the high prevalence of sleep disturbances in MSA patients.